A novel cholecystokinin type-B receptor antagonist named tetronothiodin has been isolated by column chromatography and preparative HPLCfrom the fermentation broth of Streptomyces sp. NR0489. Tetronothiodin inhibited the binding of CCK8(C-terminal octapeptide of cholecystokinin) to rat cerebral cortex membranes (CCK type-B receptors) with an IC50 of 3.6nM, whereas it did not inhibit CCK8binding to rat pancreatic membranes (CCK type-A receptors). It also inhibited CCK8induced Ca2+ mobilization in GH3cells, a rat anterior pituitary cell line, but was without effect on the basal cytosolic Ca2+ concentration. This finding indicated tetronothiodin was an antagonist of CCKtype-B receptors.
A novel cholecystokinin type-B receptor antagonist named tetronothiodin has been isolated by column chromatography and preparative HPLCfrom the fermentation broth of Streptomyces sp. NR0489. Tetronothiodin inhibited the binding of CCK8(C-terminal octapeptide of cholecystokinin) to rat cerebral cortex membranes (CCK type-B receptors) with an IC50 of 3.6nM, whereas it did not inhibit CCK8binding to rat pancreatic membranes (CCK type-A receptors). It also inhibited CCK8induced Ca2+ mobilization in GH3cells, a rat anterior pituitary cell line, but was without effect on the basal cytosolic Ca2+ concentration. This finding indicated tetronothiodin was an antagonist of CCKtype-B receptors. Cholecystokinin (CCK) is a hormonal regulator of pancreatic secretion1* as well as gallbladder contraction2* and gut motility3). It has also been proposed to act as a neurotransmitter in the central nervous system4*. CCKtype-B (CCK-B)receptors are suggested to be related to appetite5*, pain6'7* and anxiety8'9*. SomeCCK-Breceptor antagonists increased food intake5*, enhanced morphine analgesia6'7* and reduced anxiety8'9* in rats. However, physiological and pharmacological roles of CCK-Breceptors
are not yet fully understood in part because of the shortage of potent and specific CCK-B receptor antagonists. To obtain structurallv unique and specific CCK-Breceptor antagonists, we screened microbial metabolites by employing a binding assay method in which rat cerebral cortex membranesand 125I labeled Bolton-Hunter CCK8 ([125I]-CCK8) were used as the receptors and the radioligand, respectively. In this screening program, we discovered a novel CCK-B receptor antagonist named tetronothiodin (1) from the culture broth of Streptomyces sp. NR0489, and determined the structure to be a macrocyclic compound containing an aacyltetronic acid and a tetrahydrothiophene ring (Fig. 1) . A preliminary communication of this work Fie. 1. Structure of tetronothiodin (1 JAN. 1993 has been reported10). Details of the taxonomy and fermentation of 1 are reported in the preceding paper11*. The structural elucidation study of 1 is reported in the succeeding paper12) in detail. In the present paper, we describe the isolation, physico-chemical characterization and biological activities of 1.
Isolation
Isolation of 1 was carried out by monitoring the inhibitory activity against 125I labeled Bolton-Hunter CCK8([125I]-CCK8) binding to rat cerebral cortex membranes. The isolation procedure of 1 is outlined in Fig. 2 . After cultivation of the producing organism for ten days in 50-literjar fermenters by the procedure described in the preceding paper1 1}, the mycelium was removed by centrifugation. The broth supernatant (181liters) was adjusted to pH 7 with 6n HC1 and applied to a column (12x 100cm) of Diaion HP-21 (Mitsubishi Chemical Industries). The column was washed with water (25 liters) and 10%aqueous acetone (50 liters), and the active principle was eluted with 50%aqueous acetone (60liters). The active eluate was concentrated to about 15 liters under reduced pressure and extracted with ethyl acetate (25 liters x 2) at pH 2. The organic layer was dried over anhydrous sodium sulfate and concentrated to 3.5liters under reduced pressure. This solution was back-extracted with water (1.5 liters x 2) at pH 7.5. The water layer was concentrated to 1.5liters under reduced pressure. The concentrate was applied to a column (5 x 16cm) of QAESephadex A-25 (Pharmacia Fine Chemicals) which was developed stepwise with water solution; it gradually decomposed during NMRexperiments for two weeks in DMSO-d6or CD3OD.Its alkaline metal salts were stable for at least five months under the same experimental conditions. The IR (Fig. 3 ) absorption bands at 3000~2300 and 1728cm"1 suggested the presence of a carboxylic acid. A Fig. 3 . IR spectrum (KBr) of tetronothiodin. Fig. 4 . UVspectrum of tetronothiodin. MeOH, MeOH-NaOH, MeOH-HQ y-lactone function was also suggested by the shoulder band at 1760cm" 1 (KBr), which clearly separated from a large carbonyl band (1728cm"1) in THF. The UVspectrum (Fig. 4) in MeOHshowed absorption maximaat 233 and 273 nm and hypochromic effect was observed in acidic methanol. These absorption maximawere attributable to an a-acyltetronic acid chromophore13> 14) with the former absorption maximum being partly due to a diene chromophore. The molecular formula (C31H38O8S) determination was based on positive ion FAB-MS and negative ion HRFAB-MSdata [569.2237, calcd for (M-H, C31H37O8S)5 69.2210]. The molecular formula was supported by the analyses of the XHNMRspectrum (Fig. 5 ) and the 13C NMRspectrum (Fig. 6) showing 31 carbon signals, and by qualitative analysis for sulfur15). These physico-chemical properties indicated that the structure of 1 was different from known CCKreceptor antagonists of microbial origin such as virginiamycin Mx analogues16), anthramycin17) and asperlicin18). The chromophore, a-acyltetronic acid, is commonlycontained in some antibiotics such as kijanimicin13), tetrocarcins14) and MM461 1519). However 1 was different from these antibiotics in terms of containing a sulfur atom in the molecule.
Biological
Activities The inhibitory activities against the binding of r125I~l-CCKo to CCK-Aand CCK-Breceptors were 10 him 2-(7V-morpholino)ethanesulfonate buffer (pH 6.5) containing NaCl 130 mM, MgCl2 5 mM, bacitracin 0.02% and bovine serum albumin (0.2% and 0% for CCK-Aand CCK-Breceptors, respectively). After equilibrium was reached (120minutes for CCK-Areceptors or 20minutes for CCK-Breceptors), each mixture was filtered by a Durapore HVLPfilter and the radioactivity of the filter was counted by an autogammacounter.
1 inhibited the binding of [125I]-CCK8 to CCK-Breceptors on rat cerebral cortex membranes in a concentration dependent manner with an IC50 of 3.6nM ( Table 2 ). The affinity to CCK-Breceptors of 1 was three or four times more potent than those of L-365,2602O) or CI-9889) knownas potent and selective CCK-Breceptor antagonists, and only three times less potent than the natural ligand CCK8(IC50 = 1.2 nM). However 1 did not inhibit the binding of [125I]-CCK8 to rat pancreatic membranes (CCK-A receptors). The ratio of the affinity for CCK-Ato CCK-Breceptors of 1 was more than 27,000, which was 90-fold greater than the -A and -B affinity ratio of L-365,260 (300). 1 was thus revealed to be a highly selective binding inhibitor of CCK-Breceptors. GH3cells were reported to express CCK-Breceptors21}. This fact was corroborated by our results that 1 inhibited CCK8binding to GH3cells with an IC50 of 4.2nM, which was of the same order as that for brain CCK-Breceptors. It had also been demonstrated that the intracellular Ca2 + concentration ([Ca2 +];) in GH3cells was increased by CCK8in a concentration dependent manner at 1 to 1,000nM22) using the Fura-2 method23). 
Discussion
The structure of 1 is completely different from natural CCK-Breceptor antagonists (virginiamycin Mxanalogues16) and anthramycin17) produced by Streptomyces sp.) and a CCKtype-A receptor antagonist (asperlicin produced by Aspergillus alliaceus1 8)) of microbial origin. It is also different from the other CCK antagonists24):
(1) cyclic nucleotides (dibutyryl cyclic GMP), (2) amino acids (proglumide, lorglumide and loxiglumide), (3) partial sequences and derivatives of the C-terminal heptapeptides ofCCK(CCK-JMV-1 80), (4) benzodiazepines (devazepide and L-365,260) and (5) nonpeptide "peptoids" derived from fragments in the CCKmolecule (CI-988). 1 is structurally related to some antibiotics such as kijanimicin13), tetrocarcins14) and MM461 1519) in terms of the macrocyclic molecule containing an a-acyltetronic acid chromophore. In contrast to these antibiotics, 1 is inactive against Bacillus subtilis and Micrococcus luteus. A CCK-Breceptor antagonist, L-365,260, increased food intake in rats5). An anxiolytic activity8'9* and JAN. 1993 enhancement of morphine analgesia6'7* by CCK-Breceptor antagonists in rats were also demonstrated by L-365,260 and CI-988. The possibility of clinical application of CCK-Breceptor antagonists was suggested by these studies. However, physiological and pharmacological roles of CCK-Breceptors are not yet fully understood partly because of the shortage of potent and specific CCK-Breceptor antagonists. 1 is a novel, potent and highly selective CCK-Breceptor antagonist. It will be a useful tool for the investigation of the physiological and pharmacological roles of CCK-Breceptors. Full details of the biological activities will be reported elsewhere25).
